S&P Futures
4,066.75 +62.00 (+1.55%) Dow Futures
32,542.00 +383.00 (+1.19%) Nasdaq Futures
12,485.75 +241.00 (+1.97%) Russell 2000 Futures
1,816.00 +33.60 (+1.89%) Crude Oil
115.34 +1.14 (+1.00%) Gold
1,834.30 +20.30 (+1.12%)
Ascendis Pharma A/S (ASND)
After hours:
Chart Events
Performance Outlook
| Previous Close | 83.12 |
| Open | 83.12 |
| Bid | 79.50 x 2200 |
| Ask | 301.51 x 1000 |
| Day's Range | 82.62 - 85.45 |
| 52 Week Range | 61.58 - 178.71 |
| Volume | |
| Avg. Volume | 593,388 |
| Market Cap | 4.824B |
| Beta (5Y Monthly) | 0.72 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.27 |
| Earnings Date | May 11, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 160.29 |
- Investor's Business Daily
Ascendis Reverses Its Losses After A Key Drug Misses Sales Forecasts
Biotech stock Ascendis Pharma reversed early losses Thursday to close with a gain despite a first-quarter miss for Skytrofa.
- GlobeNewswire
Ascendis Pharma A/S Reports First Quarter 2022 Financial Results
Phase 3 PaTHway Trial top-line results demonstrated potential of TransCon™ PTH to become the first parathyroid replacement therapy for adults with hypoparathyroidismTransCon PTH U.S. FDA regulatory submission on track for Q3 and EU MAA for Q4 2022 Increasing uptake of SKYTROFA® (lonapegsomatropin-tcgd), with more than 1,200 unique patient prescriptions processed as of April 29, 2022Completed U.S. $575 million convertible notes offering strengthening balance sheet to build a sustainable leading g
- Zacks
Why Ascendis Pharma (ASND) Might Surprise This Earnings Season
Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
